Jonathan Goldberg, BS
Jonathan Goldberg graduated from the University of Miami in 2015 with a BS in Biology and minors in mathematics, chemistry and psychology. In 2016, Jonathan enrolled in the University of Texas McGovern Medical School in Houston and is currently a 4th year medical student.
During his college years, he spent his summers as a research assistant at MD Anderson. During the first summer he worked in Dr. Steven Curley’s Liver Cancer lab where he worked on growing cancer stem cells on a 3D culture. While in the Curley lab, he also worked on the “Kanzius project,” which involved targeting Liver cancer cells with gold nanoparticles and subsequently melting the nanoparticles with radio waves. Later in college, He joined Dr. Jason Flemming’s pancreatic cancer lab where he worked co-culturing pancreatic cells and fibroblasts in a 3d culture to better understand the Tumor Microenvironment.
While in medical school, Jonathan joined Dr. Mittendorf’s Breast surgical Oncology lab at MD Anderson where he focused on the immunogenicity of Estrogen Receptor (ESR1) mutations and their potential role as targets for vaccine-based immunotherapy.
Jonathan was delighted to receive the opportunity between his 3rd and 4th years of medical school to pursue research at DFCI under the BTIL. Working as a graduate student in the lab, Jonathan continues to work on his “team vaccine” project but has broadened his interests into other methods of detecting novel targets for Breast Cancer treatment. To do this, he is studying the tumor microenvironment of Hormone Receptor positive (HR+) Breast tissue via a combination of two cutting edge technologies: single cell RNA Sequencing (scRNA-Seq) and Cyclic Immunofluorescence (CyCIF). In doing this, he will be analyzing the full transcriptome of the tumor cells, immune cells, and other players in the TME such as fibroblasts. In addition, Jonathan is working on optimizing another novel technology, Mass Cytometry (CyTOF), for future studies into the TME. Lastly, he is also leading a clinical retrospective project to study the outcomes of patients considered “low ER+” (1-10% of cancer cells express ER), a population of cancer patients in which the standard of care is not supported by strong evidence based medicine.
Interests Outside of Lab
Basketball, boxing, doing “UWORLD” questions, and spending time with his adorable one-year-old niece: Sophie